Phase I Study of LNF1901 in Advanced Malignant Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2027

Conditions
Advanced Malignant Tumors
Interventions
DRUG

LNF1901 Monoclonal Antibody Injection

LNF1901,7 dose groups:0.003mg/kg、0.03mg/kg、0.1mg/kg、0.3mg/kg、1mg/kg、2mg/kg、3mg/kg,IV, infusion time 60min±10min, Q3W, until disease progression or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.

All Listed Sponsors
collaborator

Sun Yat-sen University

OTHER

lead

Shandong New Time Pharmaceutical Co., LTD

INDUSTRY